These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

295 related items for PubMed ID: 22011982

  • 1. Lorcaserin: an investigational serotonin 2C agonist for weight loss.
    Hurren KM, Berlie HD.
    Am J Health Syst Pharm; 2011 Nov 01; 68(21):2029-37. PubMed ID: 22011982
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Lorcaserin: a novel serotonin 2C agonist for the treatment of obesity.
    Nigro SC, Luon D, Baker WL.
    Curr Med Res Opin; 2013 Jul 01; 29(7):839-48. PubMed ID: 23574263
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of lorcaserin in obesity: a systematic review and meta-analysis of randomized controlled trials.
    Singh AK, Singh R.
    Expert Rev Clin Pharmacol; 2020 Feb 01; 13(2):183-190. PubMed ID: 31815555
    [Abstract] [Full Text] [Related]

  • 10. Lorcaserin. In obesity: unacceptable risks.
    Prescrire Int; 2014 May 01; 23(149):117-20. PubMed ID: 24926508
    [Abstract] [Full Text] [Related]

  • 11. Safety and efficacy of lorcaserin: a combined analysis of the BLOOM and BLOSSOM trials.
    Aronne L, Shanahan W, Fain R, Glicklich A, Soliman W, Li Y, Smith S.
    Postgrad Med; 2014 Oct 01; 126(6):7-18. PubMed ID: 25414931
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. ACS chemical neuroscience molecule spotlight on Lorcaserin.
    Hopkins CR.
    ACS Chem Neurosci; 2010 Nov 17; 1(11):718-9. PubMed ID: 22778808
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Lorcaserin Hcl for the treatment of obesity.
    Shukla AP, Kumar RB, Aronne LJ.
    Expert Opin Pharmacother; 2015 Nov 17; 16(16):2531-8. PubMed ID: 26472579
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Lorcaserin: A review of its preclinical and clinical pharmacology and therapeutic potential.
    Higgins GA, Fletcher PJ, Shanahan WR.
    Pharmacol Ther; 2020 Jan 17; 205():107417. PubMed ID: 31629010
    [Abstract] [Full Text] [Related]

  • 19. Lorcaserin: drug profile and illustrative model of the regulatory challenges of weight-loss drug development.
    Bays HE.
    Expert Rev Cardiovasc Ther; 2011 Mar 17; 9(3):265-77. PubMed ID: 21438803
    [Abstract] [Full Text] [Related]

  • 20. Directly Observable Behavioral Effects of Lorcaserin in Rats.
    Serafine KM, Rice KC, France CP.
    J Pharmacol Exp Ther; 2015 Dec 17; 355(3):381-5. PubMed ID: 26384326
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.